MPA and P4 have different biological effects, such as affinities for PR, unique intracellular signaling pathways, potencies, metabolism, pharmacokinetics, efficacy, side effects, and off-target effects based on their different structures [34], and they also have different risks of breast cancer [8]. The gene discussed is PGR; the disease is breast carcinoma.